Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling

Xiaozheng Zhang, Yinghua Peng, Peter M. Grace, Matthew D. Metcalf, Andrew J. Kwilasz, Yibo Wang, Tianshu Zhang, Siru Wu, Brandon R. Selfridge, Philip S. Portoghese, Kenner C. Rice, Linda R. Watkins, Mark R. Hutchinson, Xiaohui Wang

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Deregulation of innate immune TLR4 signaling contributes to various diseases including neuropathic pain and drug addiction. Naltrexone is one of the rare TLR4 antagonists with good blood-brain barrier permeability and showing no stereoselectivity for TLR4. By linking 2 naltrexone units through a rigid pyrrole spacer, the bivalent ligand norbinaltorphimine was formed. Interestingly, (+)-norbinaltorphimine [(+)-1] showed ∼25 times better TLR4 antagonist activity than naltrexone in microglial BV-2 cell line, whereas (–)-norbinaltorphimine [(–)-1] lost TLR4 activity. The enantioselectivity of norbinaltorphimine was further confirmed in primary microglia, astrocytes, and macrophages. The activities of meso isomer of norbinaltorphimine and the molecular dynamic simulation results demonstrate that the stereochemistry of (+)-1 is derived from the (+)-naltrexone pharmacophore. Moreover, (+)-1 significantly increased and prolonged morphine analgesia in vivo. The efficacy of (+)-1 is long lasting. This is the first report showing enantioselective modulation of the innate immune TLR signaling.—Zhang, X., Peng, Y., Grace, P. M., Metcalf, M. D., Kwilasz, A. J., Wang, Y., Zhang, T., Wu, S., Selfridge, B. R., Portoghese, P. S., Rice, K. C., Watkins, L. R., Hutchinson, M. R., Wang, X. Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling. FASEB J. 33,9577-9587 (2019). www.fasebj.org.

Original languageEnglish (US)
Pages (from-to)9577-9587
Number of pages11
JournalFASEB Journal
Volume33
Issue number8
DOIs
StatePublished - Aug 1 2019

Bibliographical note

Funding Information:
The authors thank the Drug Supply Program of National Institute of Drug Abuse (Bethesda, MD, USA) for providing (?)-norbinaltorphimine. The authors also thank the Network and Coumputing Center, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, National Supercomputer Center of China in Guangzhou and the Computing Center of Jilin Province for the supply of computational resources. This work was supported by the National Key Research and Development Program of China (2016YFC0800907), the National Natural Science Foundation of China (21850410455, 21750110432, 21877106), the 100 Talents Program of Chinese Academy of Sciences, Young Talents Program of Chinese Academy of Agricultural Sciences, Central Public-interest Scientific Institution Basal Research Fund (NO.1610342016013), Natural Science Foundation of Jilin Province (20180101021JC), Open Fund of State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University (Grant No. KF-GN-201601), and U.S. National Institutes of Health (NIH) National Institute of Dental and Craniofacial Research Grant R01 DE017782 (to L.R.W.). The authors declare no conflicts of interest.

Publisher Copyright:
© FASEB

Keywords

  • MD-2
  • TLR4
  • enantioselective modulation
  • morphine analgesia
  • norbinaltorphimine

Fingerprint Dive into the research topics of 'Stereochemistry and innate immune recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling'. Together they form a unique fingerprint.

Cite this